Africa Business Radio

Drugmaker AstraZeneca says that its COVID-19 antibodies’ cocktail has helped cut the risk of severe disease or deaths in a late-stage study.The pharma company announced the results marking a boost in its effort to develop coronavirus medicines beyond vaccines.The drug, a mix of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50 per cent in non-hospitalised patients who have had symptoms for seven days or fewer, meeting the main goal of the study.The trial’s principal investigator, Hugh Montgomery, says these positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic.